AbbVie bought an exclusive right to acquire San Francisco-based Mitokinin after the company completes its Investigational New Drug (IND)-enabling studies on its lead program, PINK1, for Parkinson’s disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,